New combo therapy for breast cancer aims to outsmart drug resistance

NCT ID NCT07395336

Recruiting now Disease control Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining two hormone-blocking drugs, elacestrant and exemestane, can help people with a certain type of advanced breast cancer (HR+/HER2-) that has stopped responding to initial treatments. The study uses a special PET scan to select participants whose tumors still have active estrogen receptors. The main goal is to see how long the cancer stays under control without growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elacestrant and exemestane (two hormone-blocking drugs)
What this could lead to: If successful, this could offer a new combination treatment option for certain patients with advanced breast cancer whose tumors still show estrogen receptors on PET scans.
What could go wrong: This is a small, early-phase study with only 26 participants. The combination may not work better than existing treatments, and side effects from the two drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

European Institute of Oncology
RECRUITING

Milan, Italy, 20141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.